ES2177967T3 - Procedimiento de inhibicion de una respuesta inmune bloqueando las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso. - Google Patents

Procedimiento de inhibicion de una respuesta inmune bloqueando las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso.

Info

Publication number
ES2177967T3
ES2177967T3 ES97916037T ES97916037T ES2177967T3 ES 2177967 T3 ES2177967 T3 ES 2177967T3 ES 97916037 T ES97916037 T ES 97916037T ES 97916037 T ES97916037 T ES 97916037T ES 2177967 T3 ES2177967 T3 ES 2177967T3
Authority
ES
Spain
Prior art keywords
immune response
ctla4
compositions
binding
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916037T
Other languages
English (en)
Other versions
ES2177967T5 (es
Inventor
Christian P Larsen
Alejandro A Aruffo
Diane L Hollenbaugh
Peter S Linsley
Jeffrey A Ledbetter
Thomas C Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Bristol Myers Squibb Co
Original Assignee
Emory University
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21761563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2177967(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emory University, Bristol Myers Squibb Co filed Critical Emory University
Application granted granted Critical
Publication of ES2177967T3 publication Critical patent/ES2177967T3/es
Publication of ES2177967T5 publication Critical patent/ES2177967T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN PROCEDIMIENTO PARA INHIBIR UNA RESPUESTA INMUNE, ASI COMO PARA INHIBIR EL RECHAZO DE TEJIDOS TRASPLANTADOS. EL PROCEDIMIENTO COMPRENDE PREVENIR QUE UNA MOLECULA ENDOGENA DE UNA CELULA SELECCIONADA ENTRE EL GRUPO FORMADO POR LOS ANTIGENOS GP39 Y CD40 FIJE SU LIGANDO ENDOGENO, E IMPEDIR QUE UNA MOLECULA ENDOGENA DE UNA CELULA SELECCIONADA DEL GRUPO FORMADO POR LOS ANTIGENOS CTLA4, CD28 Y B7 FIJEN SU LIGANDO ENDOGENO. LA PREVENCION DE TALES MOLECULAS DE LA FIJACION DE SU LIGANDO BLOQUEA DE ESE MODO DOS VIAS INDEPENDIENTES DE SEÑALIZACION E INHIBE LA RESPUESTA INMUNE QUE PROVOCA EL RECHAZO DEL TEJIDO TRASPLANTADO.
ES97916037T 1996-03-20 1997-03-20 Procedimientos para inhibir una respuesta inmune mediante bloqueo de las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso. Expired - Lifetime ES2177967T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1375196P 1996-03-20 1996-03-20
US13751P 1996-03-20

Publications (2)

Publication Number Publication Date
ES2177967T3 true ES2177967T3 (es) 2002-12-16
ES2177967T5 ES2177967T5 (es) 2009-12-17

Family

ID=21761563

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916037T Expired - Lifetime ES2177967T5 (es) 1996-03-20 1997-03-20 Procedimientos para inhibir una respuesta inmune mediante bloqueo de las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso.

Country Status (13)

Country Link
US (4) US5916560A (es)
EP (1) EP0892643B2 (es)
JP (1) JP4751493B2 (es)
AT (1) ATE219376T1 (es)
AU (1) AU710998B2 (es)
CA (1) CA2246352C (es)
DE (1) DE69713499T3 (es)
DK (1) DK0892643T4 (es)
ES (1) ES2177967T5 (es)
IL (1) IL125928A (es)
NO (1) NO326922B1 (es)
PT (1) PT892643E (es)
WO (1) WO1997034633A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
KR100575069B1 (ko) * 1997-05-17 2006-05-02 바이오겐 아이덱 엠에이 인코포레이티드 역적응성 면역 반응, 특히 이식 거부반응을 예방하기 위한ｃｄ40:ｃｄ154 결합 저해제의 용도
IL133070A0 (en) * 1997-06-11 2001-03-19 Us Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
HUP0003160A3 (en) * 1997-06-20 2002-09-30 Biogen Idec Ma Inc Cambridge The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
ATE319825T1 (de) * 1997-11-07 2006-03-15 Trillium Therapeutics Inc Verfahren und zusammensetzungen zur immunomodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1053006A4 (en) 1998-02-04 2002-09-25 Gen Hospital Corp COSTIMULATORY BLOCKADE AND MIXED CHIMERISM IN TRANSPLANTATIONS
US6841347B1 (en) 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
KR100711210B1 (ko) * 1998-07-30 2007-04-24 리젼츠 오브 더 유니버시티 오브 미네소타 ｇｐ３９ 길항제를 사용한 동종 또는 이종 Ｔ-세포의 생체외 처리
IL142069A0 (en) * 1998-09-21 2002-03-10 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
WO2000039294A1 (en) * 1998-12-24 2000-07-06 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
JP3581660B2 (ja) 1999-04-30 2004-10-27 ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー 潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法
EP1642596A3 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
AU1072701A (en) * 1999-10-04 2001-05-10 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2926401A (en) * 2000-01-03 2001-07-16 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
AU2001247401A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN1438894A (zh) * 2000-06-09 2003-08-27 布里斯托尔-迈尔斯斯奎布公司 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法
SK287940B6 (sk) * 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1341902A2 (en) * 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002083162A1 (en) * 2001-04-13 2002-10-24 University Of Chicago Use of a cd8+ t cell inhibitory agent in the presence of a cd4+ t cell inhibitory agent for inhibition of transplant rejection
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
JP4837880B2 (ja) 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
RU2353384C2 (ru) * 2003-08-04 2009-04-27 Бристол-Маерс Сквибб Компани Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
CA2535583A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
EP1912675B1 (en) * 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-cell reduction using cd37-specific and cd20-specific binding molecules
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
EP2185593B1 (en) * 2007-07-25 2017-12-13 Alexion Pharmaceuticals, Inc. Compositions for treating autoimmune disease
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
JP6013733B2 (ja) * 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
EP3229586A4 (en) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
KR20230110373A (ko) * 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
CA2086325C (en) * 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2580812A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ATE155043T1 (de) * 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
CN100341896C (zh) * 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
EP0832227B9 (en) * 1995-06-05 2006-06-28 University of Washington Method for prolonging the expression of a gene of interest using soluble ctla4 molecules
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN1438894A (zh) * 2000-06-09 2003-08-27 布里斯托尔-迈尔斯斯奎布公司 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SK287940B6 (sk) * 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
JP4837880B2 (ja) * 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法

Also Published As

Publication number Publication date
PT892643E (pt) 2002-09-30
DE69713499T3 (de) 2010-05-06
WO1997034633A1 (en) 1997-09-25
ES2177967T5 (es) 2009-12-17
US20050202011A1 (en) 2005-09-15
NO326922B1 (no) 2009-03-16
US20090186037A1 (en) 2009-07-23
NO984369L (no) 1998-11-18
EP0892643B2 (en) 2009-09-02
US20020031510A1 (en) 2002-03-14
CA2246352A1 (en) 1997-09-25
AU710998B2 (en) 1999-10-07
NO984369D0 (no) 1998-09-18
DE69713499T2 (de) 2003-01-30
DK0892643T4 (da) 2009-12-14
JP4751493B2 (ja) 2011-08-17
CA2246352C (en) 2011-11-08
IL125928A0 (en) 1999-04-11
US5916560A (en) 1999-06-29
EP0892643B1 (en) 2002-06-19
DE69713499D1 (de) 2002-07-25
IL125928A (en) 2002-11-10
AU2331097A (en) 1997-10-10
DK0892643T3 (da) 2002-10-14
JP2001518066A (ja) 2001-10-09
ATE219376T1 (de) 2002-07-15
EP0892643A1 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
ES2177967T3 (es) Procedimiento de inhibicion de una respuesta inmune bloqueando las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso.
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
DK0695758T3 (da) Pentapeptidamider og -estere til inhibering af human cancer
MX9707431A (es) Inhibidores de la proteina cinasa c.
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
ITMI950493A0 (it) Frazioni polifenoliche di te' loro uso e formulazioni che le contengono
BR9707819A (pt) Imunogenos peptidicos
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
MY125587A (en) Protien kinase c inhibitors.
TR199900310T2 (xx) Trombin inhibit�rleri
ES2133543T3 (es) Derivados de pirrolidina y oxazolidina, su preparacion y su uso como inhibidores de la agregacion de trombocitos.
DK1053239T3 (da) Gluccocorticoid-selektive, anti-inflammatoriske midler
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
AR024138A1 (es) Inhibidores de la proliferacion celular
PT1053240E (pt) Agentes anti-inflamatorios selectivos para glucocorticoides
BR9913533A (pt) Processos para tratar hipertensão e composições para uso nos mesmos
DK0759687T3 (da) Anvendelse af gelpræparater som bejdsemidler
SE9802937D0 (sv) Novel compounds
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
DK1107789T3 (da) Sammensætninger og metoder til beskyttelse af organer, væv og celler mod beskadigelse formidlet af immunsystemet
DK1313504T3 (da) Fremgangsmåder og sammensætninger til hæmning af angiogenese
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1067138A4 (en) HYDROXYPROLINE DERIVATIVES
ATE306929T1 (de) Inositolphosphoglycan und ribose zur behandlung von ischämischen-reperfusionschaden